jmo, not investment advice...

While they were obviously circumspect based on all that is going on there, mgmt estimates that ~150k leg stents are placeed annually and that somewhere between "high teens and 70% of those will restenos within 12 months" with many such cases being acute and requiring clinician action.

As they put it, ~getting the 510k approval to do leg ISR procedures will likely be the source of "a lot of porcedures", but they obviously need to maintain a low profile on "promotion" until they have the indication in hand (say nothing of the current "investigation" getting wrapped up).

If ISR does gain the visible potential, imo that will be a major upside catalyst here, even if they continue to stumble on the pad lasing atherectomy opportunity.

In what seems like an old hat now, they think they have new sales folks and plans to make atherectomy better and want to continue to make progress on other business lines by focusing on good execution and driving procedures blah blah.

discl. still long and feeling patient on the potential of ISR (along with lead mgmt) to be spnc's golden goose application.